Mesh.i
Exploration
Accueil
Racine
Exploration
Accueil
Racine

La maladie de Parkinson au Canada (serveur d'exploration) - Exploration (Accueil)

Index « Mesh.i » - entrée « Drug Administration Schedule »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Drug Administration Routes < Drug Administration Schedule < Drug Approval  Facettes :

List of bibliographic references indexed by Drug Administration Schedule

Number of relevant bibliographic references: 16.
Ident.Authors (with country if any)Title
000265 (2016) Priti Gros [Canada] ; Victoria P. Mery [Chili] ; Anne-Louise Lafontaine [Canada] ; Ann Robinson [Canada] ; Andrea Benedetti [Canada] ; R John Kimoff [Canada] ; Marta Kaminska [Canada]Obstructive sleep apnea in Parkinson's disease patients: effect of Sinemet CR taken at bedtime.
000568 (2015) Constant V. M. Verschuur [Pays-Bas] ; S. R. Suwijn [Pays-Bas] ; B. Post [Pays-Bas] ; M. Dijkgraaf [Pays-Bas] ; B. R. Bloem [Pays-Bas] ; J. J. Van Hilten [Pays-Bas] ; T. Van Laar [Pays-Bas] ; G. Tissingh [Pays-Bas] ; G. Deuschl [Allemagne] ; A. E. Lang [Canada] ; R. J. De Haan [Pays-Bas] ; R. M. A. De Bie [Pays-Bas]Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EArly Parkinson’s disease: the LEAP-study
000742 (2015) Eric J. Lenze [États-Unis] ; Benoit H. Mulsant [Canada] ; Daniel M. Blumberger [Canada] ; Jordan F. Karp [États-Unis] ; John W. Newcomer [États-Unis] ; Stewart J. Anderson [États-Unis] ; Mary Amanda Dew [États-Unis] ; Meryl A. Butters [États-Unis] ; Jacqueline A. Stack [États-Unis] ; Amy E. Begley [États-Unis] ; Charles F. Reynolds [États-Unis]Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial.
000D42 (2013) Nicolas Morin [Canada] ; Laurent Grégoire ; Marc Morissette ; Sandrine Desrayaud ; Baltazar Gomez-Mancilla ; Fabrizio Gasparini ; Thérèse Di PaoloMPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.
001E63 (2009) Sotirios A. Parashos [États-Unis] ; Christopher J. Swearingen ; Kevin M. Biglan ; Ivan Bodis-Wollner ; Grace S. Liang ; G Webster Ross ; Barbara C. Tilley ; Lisa M. ShulmanDeterminants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience.
002148 (2008) Leonardo Cortese [Canada] ; Michael P. Caligiuri ; Richard Williams ; Peter Schieldrop ; Rahul Manchanda ; Ashok Malla ; Raj HarricharanReduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia.
002169 (2008) M. Jog [Canada] ; M. Panisset ; O. Suchowersky ; B. Réhel ; R. SchecterNaturalistic evaluation of entacapone in patients with signs and symptoms of L-dopa wearing-off .
002212 (2008) Jiang Yue [Canada] ; Sharon Miksys ; Ewa Hoffmann ; Rachel F. TyndaleChronic nicotine treatment induces rat CYP2D in the brain but not in the liver: an investigation of induction and time course.
002308 (2008) Susan H. Fox [Canada] ; Anthony E. Lang [Canada]Levodopa‐related motor complications—Phenomenology
002E98 (2003) Pierre J. Blanchet [Canada]The fluctuating Parkinsonian patient: Clinical and pathophysiological aspects
002F47 (2003) Nancy Belanger [Canada] ; Laurent Gregoire [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; Paul J. Bedard [Canada]Chronic treatment with small doses of cabergoline prevents Dopa-induced dyskinesias in Parkinsonian monkeys
002F82 (2002) Philip Seeman [Canada]Atypical antipsychotics: mechanism of action.
003252 (2001) Gerlinde A. S. Metz ; Tracy Farr ; Mark Ballermann ; Ian Q. WhishawChronic levodopa therapy does not improve skilled reach accuracy or reach range on a pasta matrix reaching task in 6‐OHDA dopamine‐depleted (hemi‐Parkinson analogue) rats
003545 (2000) Frédéric Calon ; Marc Morissette ; Martin Goulet ; Richard Grondin ; Pierre J. Blanchet ; Paul J. Bédard ; Thérèse Di Paolo125I-CGP 64213 Binding to GABAB Receptors in the Brain of Monkeys: Effect of MPTP and Dopaminomimetic Treatments
003E98 (1996) M. Goulet [Canada] ; R. Grondin ; P. J. Blanchet ; P. J. Bedard ; T. Di Paolo [Canada]Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode to not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys
004B44 (1988) G. Chouinard [Canada]The use of benzodiazepines in the treatment of manic-depressive illness.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Mesh.i -k "Drug Administration Schedule" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Mesh.i  \
                -Sk "Drug Administration Schedule" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Mesh.i
   |clé=    Drug Administration Schedule
}}
Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022